InsidersTradesSigma
Follow the Pharvaris N.V. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Pharvaris N.V. has logged 61 reports. Market capitalisation: €2.5bn. The latest transaction was reported on 18 August 2026 (Cession). Among the most active insiders: Lesage Anne. Every trade is openly available.
61
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€5m
26 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Pharvaris N.V. Strong Buy (bullish), based on 14 analysts. Average price target: US$48.78.
39Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 18 August 2026
Declarations61 total
2,292 shares@ US$34.7669Common StockSEC:0001193125-26-354965:0
2,292 shares@ US$34.97140.0033% mcap10.3% of flowCommon StockSEC:0001193125-26-304445:0
2,292 shares@ US$35.070.0033% mcap100.0% of flowCommonSEC144:0001950047-26-007050
27,872 shares@ US$34.710.040% mcap72.9% of flowCommonSEC144:0001950047-26-006659
30,703 shares@ US$34.710.044% mcap77.2% of flowCommonSEC144:0001950047-26-006660
30,712 shares@ US$34.710.044% mcap77.2% of flowCommonSEC144:0001950047-26-006658
8,300 shares@ US$34.010.012% mcap21.3% of flowCommonSEC144:0001950047-26-006614
6,997 shares@ US$34.010.0097% mcap17.2% of flowCommonSEC144:0001950047-26-006615
6,888 shares@ US$34.010.0096% mcap17.0% of flowCommonSEC144:0001950047-26-006623
2,400 shares@ US$33.290.0033% mcap5.8% of flowCommonSEC144:0001950047-26-006496
2,300 shares@ US$33.290.0031% mcap5.8% of flowCommonSEC144:0001950047-26-006497
2,300 shares@ US$33.290.0031% mcap5.6% of flowCommonSEC144:0001950047-26-006498
2,291 shares@ US$30.720.0028% mcap100.0% of flowCommonSEC144:0001950047-26-006130
2,670 shares@ US$30.87080.0033% mcap100.0% of flowCommonSEC144:0001950047-26-005678
10,000 shares@ US$8.050.0033% mcap21.5% of flowCommon StockSEC:0001193125-26-236432:0
10,000 shares@ US$29.31660.012% mcap78.5% of flowCommon StockSEC:0001193125-26-236432:1
8,748 shares@ US$29.81990.011% mcap100.0% of flowCommon StockSEC:0001193125-26-231281:0
25 of 61 declarations
关于 Pharvaris N.V.
Pharvaris N.V. 是一家在美国上市的生物制药公司，在纳斯达克交易，股票代码为 PHVS，其运营总部位于瑞士楚格，并通过 SEC 履行美国市场报告义务。对于投资者而言，该公司符合晚期专业生物技术公司的特征，专注于缓激肽介导的疾病，特别是遗传性血管性水肿 (HAE) 和 C1 抑制剂缺乏引起的获得性血管性水肿 (AAE-C1INH)。其核心科学理念围绕新型口服缓激肽 B2 受体拮抗剂构建，旨在解决疾病领域中未满足的需求，其中便利性、缓解速度和发作预防仍然是核心商业和临床问题。([ir.pharvaris.com](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-reports-fourth-quarter-and-full-year-2025-financial?utm_source=openai)) Pharvaris 成立于 2020 年代初期，此后发展成为一家临床阶段公司，其主要资产是 deucrictibant。该项目包括速释胶囊和缓释片剂两种制剂。HAE 的积极 2 期数据支持其进入关键性开发阶段，公司目前正在 CHAPTER-3（一项预防 HAE 发作的 3 期研究）和 RAPIDe-3（一项按需治疗的 3 期研究）中评估 deucrictibant。2024 年，Pharvaris 还将开发计划扩展到 AAE-C1INH，将潜在的商业机会扩展到经典遗传病之外。([ir.pharvaris.com](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-reports-fourth-quarter-and-full-year-2024-financial?utm_source=openai)) 从竞争角度来看，Pharvaris 正试图通过口服机制和对患者友好的给药方案，在相对集中的 HAE 市场中脱颖而出。这很重要，因为现有的 HAE 疗法通常在疗效上竞争，但可能受给药途径、便利性或给药负担的限制。因此，Pharvaris 似乎定位为专注的挑战者，而非广泛的平台生物技术公司：其上行空间在很大程度上取决于临床疗效、安全性、监管进展以及获批后的最终市场采纳。该公司还利用融资来支持开发，这突显了晚期生物技术执行的资金密集型性质。([ir.pharvaris.com](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-reports-fourth-quarter-and-full-year-2024-financial?utm_source=openai)) 从地理上看，Pharvaris 具有国际足迹：在瑞士设有公司，可进入美国资本市场，并开展全球临床开发活动。近期亮点包括 2024 年全年业绩、2025 年和 2026 年的后续业务更新以及 3 期研究的持续推进。对于市场背景，PHVS 因此最好被视为一家在纳斯达克上市的美国公司，拥有一个位于欧盟的运营中心和以管线为驱动的股权故事，对临床结果、监管里程碑以及 SEC Form 4 备案等内部交易披露高度敏感。([ir.pharvaris.com](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-reports-fourth-quarter-and-full-year-2024-financial?utm_source=openai))
